Sluiten
Exploring the exposure-response relationship of Guselkumab in chronic plaque Psoriasis: Preliminary results
Rani Soenen
Blocking Interleukin-17 in Psoriasis: Real-world experience from the PsoPlus cohort
Lisa Schots
Psoriasis in the Belgian population: Prevalence of comorbidities
Heleen Cokelaere
Tom Hillary
Nectin-4-directed oncologic therapies, what to expect as a dermatologist?
Evelyn Meulewaeter
Linda Temmerman
The impact of the COVID-19 pandemic on the incidence and thickness of cutaneous melanoma in Belgium
P.G. Demaerel
A cohort study of older adults receiving Mohs micrographic surgery for a facial basal cell carcinoma: should we waive MMS in certain patients?
Laura Van Coile
Vitamin D receptor expression in cutaneous melanoma tissue: Prognostic properties and influencing factors
Julie De Smedt
Acute pancreatitis induced by topical Isotretinoin, an unprecedented association
Thomas Damsin
Prognostic value of the Vitiligo disease activity signs
Liesbeth Delbaere
Deucravacitinib, an oral, selective, Allosteric Tyrosine Kinase 2 Inhibitor, versus placebo and Apremilast in moderate to severe plaque Psoriasis: Analysis of body surface area involvement in the phase 3 POETYK PSO-1 and PSO-2 trials
Jo Lambert
Initial report on the month 12 results from the Psoriasis Study of Health Outcomes (PSoHO) for patients with moderate-to-severe psoriasis treated with biologics in the real-world setting
L. Ghys
Ixekizumab demonstrates comprehensive Psoriasis clearance in patients with moderate-to-severe Psoriasis with scalp, nail, and/or palmoplantar involvement: UNCOVER-1, -2 trials through 5 years
L. Ghys
Disease severity and implementation of the Belgian T2T guidelines in moderate-to-severe plaque Psoriasis: Results from the Belgian REDISCOVER study
L.F.E Ghys
Trajectories for scalp hair regrowth in patients with severe Alopecia Areata treated with Baricitinib
L. Ghys
Maintained improvement in patient rated outcomes with Baricitinib 4-mg in adults with moderate to severe Atopic Dermatitis who were treated for up to 104 weeks in randomised controlled trials
L. Ghys
Safety of Baricitinib for the treatment of Atopic Dermatitis over a median of 1.6 and up to 3.9 years treatment: An updated integrated analysis of 8 clinical trials
L. Ghys
Secukinumab in moderate to severe Hidradenitis Suppurativa: Primary endpoint analysis from the SUNSHINE and SUNRISE phase 3 trials
Farida Benhadou